Sector News

Shanghai Pharma bids for U.S. Cardinal Health's China business

October 19, 2017
Life sciences

Shanghai Pharmaceuticals Holding Co has bid for Cardinal Health Inc’s China business as the U.S. company looks to sell ahead of China’s planned drug distribution reform.

Shanghai Pharma submitted two non-binding bids to buy Cardinal Health China, one of the country’s largest drug distributors, on July 21 and Sept. 15, it said in a filing with the Shanghai stock exchange on Wednesday.

The company, backed by the Shanghai government, did not disclose the financial terms but said it has not entered into exclusive talks with the seller.

Reuters first reported in July that Cardinal Health had put its China business up for sale in a deal that could fetch between $1.2 billion and $1.5 billion.

The sale has drawn keen interest from state-backed Chinese pharmaceuticals companies and private equity firms such as FountainVest, said sources with knowledge of the matter.

Cardinal’s China business, which operates 16 distribution centers in 20 cities, generated more than $3.5 billion in revenue last year, compared with $3 billion in 2015, according to its earnings report.

It has hired Lazard as an adviser for the China sale, according to the sources.

FountainVest did not respond immediately to requests for comment and Lazard declined to comment. The sources asked not to be identified because the talks are not public.

Beijing in January introduced a so-called “two-invoice” procurement system for drug distribution on a trial basis as part of a broader overhaul of the country’s fragmented healthcare sector.

Under the new system, expected to be fully implemented in 2018, drug manufacturers can only work with a single distributor that directly supplies products to healthcare facilities such as hospitals.

The policy is likely to squeeze margins for many distributors that lack links to strong manufacturers and healthcare facilities in China.

In spite of the overhaul, state-owned pharma companies with strong backing from Beijing to create “national champions” in key industries have been looking to expand.

Shanghai Pharma, for example, said in August that it was bidding for a stake in U.S. specialty drugmaker Arbor Pharmaceuticals.

By Julie Zhu

Source: Reuters

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach